Case Study 1: Purdue Pharma and the Marketing of OxyContin in Coal Country

The Strategy

In 1996, when Purdue Pharma prepared to launch OxyContin, the company faced a marketing challenge. Opioids had a reputation — deserved — for being addictive. Physicians were cautious about prescribing them for chronic, non-cancer pain. The medical establishment's general approach to opioid prescribing was conservative: use opioids for acute pain and cancer pain, but avoid long-term opioid therapy for conditions like back pain, arthritis, and the chronic musculoskeletal complaints that filled primary care offices.

Purdue Pharma's strategy was to change that understanding. The company needed physicians to believe that OxyContin was fundamentally different from other opioids — that its time-release formulation made it safe for long-term use, that addiction was rare when the drug was used "as directed," and that the bigger problem was not overprescription but underprescription — that millions of Americans were suffering needlessly because physicians were too cautious about pain management.

This message was not delivered through a few advertisements. It was delivered through one of the most aggressive, sophisticated, and ultimately devastating pharmaceutical marketing campaigns in American history.

The Sales Force

Purdue Pharma built a large and lavishly compensated sales force dedicated entirely to promoting OxyContin. By the early 2000s, the company employed more than a thousand sales representatives — an extraordinary number for a company whose flagship product was a single drug.

These representatives were deployed with precision. Purdue used prescribing data purchased from data-mining companies to identify the physicians who prescribed the most opioids and the regions with the highest rates of pain complaints. The data pointed them, repeatedly, to the same places: the coalfields of West Virginia, eastern Kentucky, southwestern Virginia, and southern Ohio. These communities had exactly the patient population that OxyContin was designed (and marketed) for: people in chronic pain from physically demanding occupations, served by overworked primary care physicians with limited access to pain management specialists.

The sales representatives were trained to address physician concerns about addiction directly, using a set of talking points that consistently minimized the risk. When physicians expressed concern that OxyContin might be addictive, representatives were instructed to reference the time-release mechanism ("the sustained-release formulation reduces the risk of abuse") and the claim of "less than one percent" addiction rates. This latter figure was derived from a brief, one-paragraph letter published in the New England Journal of Medicine in 1980 by Dr. Hershel Jick, which noted that among hospitalized patients who received opioids for acute pain, addiction was rare. The letter was not a study. It did not address outpatient prescribing. It did not address chronic pain. It did not address OxyContin specifically. But Purdue Pharma cited it thousands of times as evidence that OxyContin was safe.

The Targeting of Appalachia

The geographic pattern of OxyContin's initial marketing was not random. Purdue focused its sales efforts on areas with high concentrations of primary care physicians (as opposed to specialists), high rates of workers' compensation claims and disability, and high rates of pain-related diagnoses. These criteria produced a target map that was, in effect, a map of the Appalachian coalfields.

Several factors made the coalfields ideal from Purdue's perspective:

High prescribing rates. Primary care physicians in the coalfields already prescribed at higher rates than the national average, because their patient populations had higher rates of pain. Purdue did not need to convince these physicians to start prescribing opioids; it needed to convince them to switch from older opioids (like Percocet or Vicodin) to OxyContin.

Limited specialist access. The absence of pain management specialists in rural Appalachia meant that primary care physicians were making pain management decisions that, in urban areas, would have been made by specialists with more training and more caution. A primary care doctor in McDowell County seeing forty patients a day did not have time for comprehensive pain assessments. They needed quick, effective solutions. OxyContin was marketed as exactly that.

Workers' compensation and disability. The coalfields had high rates of workers' compensation claims and Social Security disability enrollment, reflecting the prevalence of mining-related injuries and diseases. These payment systems covered prescription medications, meaning that cost was not a barrier to prescribing OxyContin — the insurance would pay.

Trust in physicians. In tight-knit Appalachian communities, the local doctor was a trusted figure. When that doctor prescribed a medication, patients took it as directed, trusting that the doctor — and by extension, the pharmaceutical company that supplied the drug — was acting in their interest.

The Conferences and the Gifts

Purdue Pharma supplemented its direct sales force with a lavish program of physician education and incentives.

The company funded continuing medical education (CME) programs — seminars and conferences that physicians attended to maintain their medical licenses — focused on pain management. These programs, nominally independent but effectively controlled by Purdue through funding and content direction, conveyed a consistent message: chronic pain was undertreated, opioids were underused, and OxyContin's time-release formulation made it a safe and appropriate choice for a wide range of chronic pain conditions.

Physicians who attended Purdue-funded CME events were sometimes held at resort destinations — a practice common in the pharmaceutical industry but particularly striking given the modesty of the coalfield physicians' usual circumstances. A primary care doctor earning $120,000 a year in a rural West Virginia practice, invited to an all-expenses-paid conference at a Florida resort, was receiving a financial benefit that, while technically legal, created an obvious conflict of interest.

Purdue also distributed branded promotional items — pens, notepads, coffee mugs, fishing hats — stamped with the OxyContin name. Sales representatives left drug samples in physician offices, allowing doctors to provide OxyContin to patients at no initial cost. The samples served a dual purpose: they introduced patients to the drug (creating demand for continued prescriptions) and they cultivated physician loyalty to the Purdue brand.

The Consequences: A Flood of Pills

The marketing campaign worked. OxyContin prescriptions surged, particularly in the communities that Purdue had targeted most aggressively.

The volume of opioids flowing into Appalachian communities reached levels that should have triggered alarm at every point in the distribution chain — manufacturer, distributor, pharmacy, prescriber. They did not.

Consider the scale: between 2006 and 2012, drug distributors shipped approximately 780 million hydrocodone and oxycodone pills to West Virginia — a state with a population of roughly 1.8 million. That is approximately 433 pills for every man, woman, and child in the state over a six-year period. In individual counties, the ratios were even more extreme. Mingo County, with a population of approximately 25,000, received over 20 million pills in a single year.

These numbers represent a catastrophic failure of the systems that were supposed to prevent exactly this outcome. The Drug Enforcement Administration (DEA) was responsible for monitoring the distribution of controlled substances and flagging suspicious shipments. Drug distributors were legally obligated to identify and report orders that were "of unusual size, or which deviate substantially from a normal pattern." Pharmacies were required to verify the legitimacy of prescriptions.

At every level, the system failed. The DEA was slow to act. Distributors shipped pills in quantities that could not possibly represent legitimate medical use without raising alarms. Pharmacies filled prescriptions that any reasonable pharmacist should have questioned. The profit motive overwhelmed the regulatory safeguards at every point in the chain.

What Purdue Knew — And When

Litigation discovery — the legal process of compelling a party to produce internal documents — revealed that Purdue Pharma had extensive knowledge of OxyContin's abuse potential and the extent to which the drug was being diverted to non-medical use.

Internal documents showed that:

• Purdue received reports of OxyContin abuse from its own sales representatives as early as 1997 — one year after the drug's launch.
• The company tracked "hotspots" of OxyContin abuse but did not alert regulators or modify its marketing in those areas.
• Company executives were aware that the time-release mechanism could be defeated by crushing the pill, but continued to market OxyContin as having abuse-deterrent properties.
• Purdue's own research indicated that the drug's effects wore off before the claimed twelve-hour dosing interval for many patients, creating periods of withdrawal that could drive dose escalation and addiction. The company's response was to instruct sales representatives to tell physicians to increase the dose rather than shorten the interval — a recommendation that increased the total amount of opioid consumed and the risk of addiction.

In 2007, Purdue Pharma and three of its executives pleaded guilty to federal charges of misbranding OxyContin — essentially, lying about its addictive potential. The company paid $634 million in fines. The executives paid $34 million in personal fines. No one went to prison.

The 2007 plea was, in retrospect, a slap on the wrist. $634 million was a fraction of the profits Purdue had earned from OxyContin. The guilty plea did not significantly reduce OxyContin prescribing. The crisis continued to escalate for another decade.

In 2020, Purdue Pharma pleaded guilty to additional federal charges, including conspiracy to defraud the United States and violating federal anti-kickback laws. The company agreed to pay $8.3 billion, though the practical value of the settlement was reduced by the company's concurrent bankruptcy filing. The **Sackler family**, which owned Purdue and had extracted approximately $10-12 billion in profits from the company between 2008 and 2018, negotiated a settlement that provided roughly $6 billion to the settlement fund in exchange for protection from future civil lawsuits — a deal that many victims' families and state attorneys general regarded as grossly inadequate.

The Moral Reckoning

The Purdue Pharma case raises questions that extend beyond the specifics of opioid marketing to the fundamental relationship between corporations and the communities they affect.

A company identified a vulnerable population. It studied that population's vulnerabilities. It designed a marketing campaign that exploited those vulnerabilities. It knew that its product was causing harm. It continued to market the product anyway. And when the harm became undeniable, it paid fines that were a fraction of its profits and shielded its owners from personal accountability.

In the coalfields, people have a word for this. They call it extraction. A resource is identified — in this case, the pain of a workforce damaged by a century of industrial labor. The resource is exploited for profit. The profits flow to people who live far away. The community is left with the wreckage.

The opioid crisis was, in this sense, a continuation of the extraction pattern that has defined Appalachian history. The coal companies extracted coal and left behind black lung, collapsed landscapes, and impoverished communities. The pharmaceutical companies extracted profit from pain and left behind addiction, overdose deaths, and shattered families. The mechanism was different. The logic was the same.

Discussion Questions

1. Purdue Pharma's marketing of OxyContin was, in most respects, legal. The company employed licensed sales representatives, distributed FDA-approved marketing materials, and promoted a legally manufactured drug. Does the legality of the marketing campaign affect your moral assessment of the company's conduct? Where should the line be drawn between aggressive marketing and public health endangerment?

2. The chapter draws a parallel between the coal industry's extraction of mineral wealth and the pharmaceutical industry's extraction of profit from chronic pain. How far does this parallel extend? In what ways are the two forms of extraction similar, and in what ways are they different?

3. Primary care physicians in the coalfields prescribed OxyContin in good faith, relying on the information provided by Purdue Pharma. To what extent were these physicians also victims of Purdue's campaign? To what extent were they complicit in the crisis?

4. The Sackler family extracted approximately $10-12 billion in personal profits from Purdue Pharma during the height of the opioid crisis. Their settlement contribution of roughly $6 billion was accompanied by protection from future civil lawsuits. Is this outcome just? What would justice look like?